卡维地洛治疗高血压病的临床研究

The clinical trial of carvedilol in treatment of hypertension

目的:评价卡维地洛治疗各级原发性高血压病的临床疗效、安全性及副作用,并对汉族、哈萨克族(哈族)两民族患者的临床疗效进行对照分析。方法:选择汉、哈族各级原发性高血压病患者各34例,均服用卡维地洛(10 mg/d)进行降压治疗,2周后疗效不满意即加量至50 mg/d,服药2、4、8、12周后分别观察血压、心率及副反应情况。结果:治疗12周后,汉族患者收缩压及舒张压的降压幅度分别为18.5%、16.3%,哈族患者收缩压及舒张压的降压幅度分别为195%、17.3%,与用药前相比差异有统计学意义(P<0.01)。治疗8周后汉族患者心率不再变化,哈族患者心率呈进一步下降趋势,12周后两者心率变化差异有统计学意义(P<0.01)。汉族和哈族患者用药前后血糖、血脂、肝肾功能均无明显变化。结论:卡维地洛对汉、哈族患者各级原发性高血压均有较好治疗作用,副作用少,但哈族患者应用时应注意监测心率变化。

Objective： To assess the effect and reliability together with difference between Han and Kazak people of carvedilol in treatment of essential hypertension. Methods： Thirty-four Han and Kazak patients with all-class essential hypertension have been enrolled to take carvedilol 10 mg per day, or accept a dose of 50 mg per day after 2 weeks, to observe blood pressure, heart rate and side effect after 2, 4, 8 and 12 weeks. Results： After 12 weeks of administration, systolic and diastolic blood pressure of Han patients decreased 18.5%,16.3% compared to that before treatment, systolic and diastolic blood pressure of Kazak patients decreased 19.5%,17.3% compared to that before treatment respectively （P 〈0.01）, there had no difference between the two groups （P〉0. 05）, but heart rate of Han patients show obvious difference from Kazak after treatment of 12 weeks （P〈0. 05）. Few side effects have been detected during the process. Conclusion： Carvedilol have nice effect on both Han and Kazak essential hypertension patients, meanwhile suffer few side effect, but heart rate should be monitor in Kazak patents.